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Abstract
Introduction: Additional nucleotide substitutions in the 3´-untranslated region of prothrombin gene could explain some thrombotic events and 
also adverse pregnancy outcomes. We describe the rst case of a homozygous 20209C>T mutation as the cause of deep vein thrombosis in a Spanish 
patient.
Case and methods: The 56-year-old male patient with a partial tear of the Achilles tendon developed calf (tibial) deep vein thrombosis after im-
mobilization and was treated with an anticoagulant. To determine if the deep vein thrombosis was of genetic origin, a peripheral blood DNA sample 
was analysed for the presence of the three most frequent mutations associated with thrombotic events: factor V Leiden (1691G>A), prothrombin 
(20210G>A) and methylene tetrahydrofolate reductase (677C>T). The presence or absence of the normal allele of prothrombin could not be deter-
mined using the PTH-FV-MTHFR StripAssay (Vienna Lab).
Results: Comprehensive analysis showed that the patient had a variant interfering with the polymerase chain reaction product, we sequenced the 
entire prothrombin gene and found that the patient had a homozygous C>T mutation at position 20209; this interfered with the polymerase chain 
reaction product, which needs a C at this position to be able to bind to the wild-type probe present in the test strip.
Conclusion: The homozygous 20209C>T mutation and the presence of the mutation 677C>T in heterozygosity explained the patient’s deep vein 
thrombosis because the combination of mutations would increase the risk of thrombosis. Suitable genetic counselling should be provided to the pa-
tient and rst-degree relatives as it important to detect prothrombin gene variants that could increase risk for thrombotic events.
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Case reports
Introduction
The human prothrombin gene spans 21 Kb on 
chromosome 11p11-q12 and consists of 14 exons 
and 13 introns accounting for 90 percent of the se-
quence. A transition (G to A) has been identi!ed at 
nucleotide 20210 in the 3´-untranslated region of 
the prothrombin gene as a risk factor for deep vein 
and cerebral venous thrombosis. Patients with 
20210G>A mutation frequently show plasma pro-
thrombin levels around a third higher than normal 
(1). The prevalence of this variant di"ers among 
populations, for example ranging from 1% to 4% 
reported for Caucasians (2). Recent investigations 
showed that variants other than 20210G>A of the 
prothrombin gene suggests that additional nucle-
otide substitutions may contribute to the develop-
ment of thrombotic events and adverse pregnan-
cy outcomes and obstetric complications (3). The 
20209C>T variant of the prothrombin gene has 
been found in individuals of African, Caucasian 
and Jewish-Moroccan origins, associated with ve-
nous thrombosis, pulmonary embolism, peripher-
al vascular disease, deep vein thrombosis, cere-
brovascular accidents (4-14) and obstetrical com-
plications (fetal loss or intrauterine growth retar-
dation) (3). Initial reports di"er as to whether or 
not this prothrombin variant is associated with an 
increased risk of venous thromboembolism (15).
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We describe the !rst homozygous 20209C>T mu-
tation for a Spanish patient who developed deep 
vein thrombosis.
Case report
The 56-year-old male patient with a partial tear of 
the Achilles tendon developed calf (tibial) deep 
vein thrombosis after immobilization and was 
treated with an anticoagulant (Sintrom). The 
aragonese patient not seemed to have a personal 
history associated with thrombotic events not rel-
evant family history. Coagulation parameters were 
determined later of acute thrombosis phase and 
the results were: free protein S 103.3% (55-150%), 
chromogenic protein C 102% (60-120%), anti-
thrombin III 86% (80-120%), homocysteine 10.04 
µmol/L (5-15 µmol/L), SCT-screen/con!rm ratio 
0.96, lupus anticoagulant screening/ con!rm ratio 
1.03, activated protein C resistance 2.74 ratio, fac-
tor VIII coagulant 119.6% (60-120%), and factor VII 
coagulant 122.9% (70-120%). Hypercoagulable 
studies were normal except for a slight increase in 
the percentage of factor VII.
Material and methods
To determine if the deep vein thrombosis was of 
genetic origin, a peripheral blood DNA sample was 
analysed for the presence of the three most fre-
quent mutations associated with thrombotic 
events: factor V Leiden (1691G>A), prothrombin 
(20210G>A) and methylene tetrahydrofolate re-
ductase (MTHFR) (677C>T).
Samples from control patients (thirty patients 
without thrombotic problems) with the sample of 
index case and his !rst-degree relatives were ana-
lyzed in genetic department.
All described studies conducted in samples from 
the index case and later of his relatives were au-
thorized by patients, who signed the correspond-
ing informed consent. The study protocol was ap-
proved by the research ethics committee of the 
government of Aragón (Spain).
Genetic analysis
In the di"erential diagnosis of thrombotic disor-
ders, genotyping of prothrombin 20210G>A is now 
performed as routine analysis. Several di"erent 
molecular genetics techniques that use restriction 
enzymes, allele-speci!c ampli!cation, hybridiza-
tion probes at a single detection temperature or 
the LightCycler system have been described (8,16-
19).
In our laboratory we used PTH-FV-MTHFR test Stri-
pAssay (Vienna Lab) (Izasa, Barcelona, Spain) based 
on the Polymerase Chain Reaction (PCR) and re-
verse hybridization/revealed using allele speci!c 
probes.The patient’s DNA extracted from EDTA 
Blood was analysed initially by method PTH-FV-
MTHFR test Strip Assay and it was found that it 
could not be determined the presence or absence 
of the normal allele of prothrombin by the method 
described. Genomic DNA was extracted from pe-
ripheral blood by standard procedures (EZ1DNA 
blood 350 µl Kit using magnetic particle technolo-
gy in EZ1 Advanced (1–6 samples per run) instru-
ment).
The PTH-FV-MTHFR test StripAssay is a test de-
signed to detect mutations in factor V (FV), pro-
thrombin (PTH) and MTHFR gene based PCR and 
hybridization reverse. The procedure consists of 
three steps: a) Isolation of DNA; b) Ampli!cation by 
PCR using primers labeled with biotin; c) Reverse 
hybridization/detection of ampli!cation products 
in a strip containing oligonucleotide probes allele-
speci!c !xed in parallel lines. The sequences la-
beled with biotin attached to the strip are detect-
ed using streptavidin-alkaline phosphatase and 
color substrate.
The sample of the patient was again analyzed two 
times more with new venous extraction and the 
same result was obtained. It was not possible to 
determine the presence or absence of the normal 
allele of phrotrombin gene.
The blood sample was analyzed with The Xpert® 
HemosIL® Factor II & Factor V Assay (Cepheid/In-
strumentation Laboratory), which is a qualitative 
in vitro diagnostic genotyping test for the detec-
tion of Factor II (20210G>A mutation) and Factor V 
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(1691G>A mutation) alleles from sodium citrate or 
EDTA anticoagulated whole blood. The GeneXpert 
Dx System automates and integrates sample puri-
!cation, nucleic acid ampli!cation, and detection 
of the target sequence in whole blood using real-
time PCR assays.
Real time-PCR, Quantitative PCR, was performed 
with the LightCycler System 2.0 (Roche Diagnos-
tics, Manheim, Germany) using the capillaries of 20 
μL. We used the LightCycler FastStart DNA Master 
Plus SYBR Green I. The hot start e"ect of FastStart 
Taq DNA polymerase minimizes the formation of 
non-speci!c products and improves sensitivity for 
the desired target. Also, we used Uracil-DNA Glyc-
osylase, heat-labile (Roche Diagnostics) 1 U for to 
eliminate PCR carry over contaminations. Fluores-
cence protocols PCR was performed with 0.2 Μm 
primers in a standard PCR reaction, supplemented. 
Samples were spun into glass capillary cuvettes, 
capped and placed in the Light-Cycler. For pro-
thrombin gene mutation, ampli!cation was per-
formed for 40 cycles of denaturation (94 °C, 0 s, 
ramp rate 20 °C/s), annealing (50 °C, 10 s, ramp rate 
20 °C/s), and extension (72 °C, 10 s, ramp rate 2 
°C/s). After ampli!cation, a melting curve was gen-
erated by holding the reaction at 50 °C for 30 s, 
and then heating slowly to 94 °C with a ramp rate 
of 0.2 °C per s. Fluorescence was collected continu-
ously during the slow temperature ramp. Melting 
curves were converted to melting peaks by plot-
ting the negative derivative of the =uorescence 
with respect to temperature (-dF/dT) against tem-
perature. The entire process takes approximately 
30 min with no separate product manipulation 
necessary. A single =uorescence reading for each 
sample was taken at the annealing step. At this 
stage of the PCR cycle both probes are allowed to 
hybridize and the total amount of product formed 
was determined by the log-linear slope intercept 
of the X-axis.
In order to con!rm the !ndings by LightCycler 
analysis it was done Sanger sequencing. The se-
quence of the prothrombin gene was ampli!ed by 
PCR using total DNA from whole blood as tem-
plate. The ampli!ed products were puri!ed and 
directly sequenced using an automated DNA se-
quencer (capillary sequencing) (model 3130, Ap-
plied Biosystems, Foster City, CA).
Prothrombin gene was individually ampli!ed by 
PCR using genomic DNA as template. Sequences 
of oligonucleotides used for ampli!cation and se-
quencing were deduced from the published Hu-
man Genome sequence (http://genome.ucsc.edu). 
Genbank Prothrombin cDNA entry with accession 
number NM_000506 was used as a reference se-
quence for analysis of mutations and numbering 
of nucleotides. Codon numbering is given for ma-
ture prothrombin protein. To identify the exact nu-
cleotide change (the wild-type C was replaced by 
a T at nucleotide position 20209), we designed PCR 
and sequencing primers (5´-CCG CCT GAA GAA 
GTG GAT A-3 a´nd 5´- CAG AGA GCT GCC CAT GAA 
T-3´ for the forward and reverse direction, respec-
tively).
Results
The results of mutations studied obtained for the 
patient and his !rst-degree family members are 
presented in summary form in Table 1. The patient 
was heterozygous for 677C>T and normal for 
1691G>A (Figure 1). The fact that it was not possi-
ble to determine the presence or absence of the 
normal allele for factor II using the FV-PTH-MTHFR 
StripAssay or the Xpert® HemosIL® Factor II & Factor 
V Assay was suggestive that the patient had a vari-
ant interfering with the PCR product. As can be 
observed from Figure 1, it was not possible to de-
termine the presence or absence of the normal al-
lele for prothrombin in the sample of index case. 
In the strips for subjects with the homozygous 
20209C>T mutation, no blue band was detected 
(wild-type 20210G>A), and in the heterozygous 
20209C>T mutation, only a partial blue band was 
detected (very little blue). Neither of the two meth-
ods con!rmed the presence or absence of the nor-
mal allele for prothrombin gene (Figure 1).
The presence of this 20209C>T mutation was con-
!rmed in another DNA sample from the patient 
and DNA samples from !rst-degree family mem-
bers were also studied to determine its presence 
or absence. Heterozygous 20209C>T was detected 
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Patient Age
Factor II 
20209C>T
Factor II 
20210G>A
Factor V Leiden 
1691G>A
MTHFR 677C>T
Clinical symptoms 
(thrombotic events)
Index case 57 Homozygous Normal Normal Heterozygous Deep vein thrombosis
Daughter 22 Heterozygous Normal Normal Homozygous Asymptomatic
Son 27 Heterozygous Normal Normal Heterozygous Asymptomatic
Mother 81 Heterozygous Normal Normal Normal Acute myocardial infarction
Father 86 Heterozygous Normal Normal Homozygous Thrombophlebitis*
Sister 47 Homozygous Normal Normal Heterozygous
Symptomatic (frequent bruising 
and varicose veins)
Brother 49 Heterozygous Normal Normal Heterozygous Asymptomatic
* Mitral valve with marked !brosis and collagen degeneration in the vicinity of the !brosis. MTHFR - methylene-tetrahydrofolate 
reductase.
TABLE 1. Status of factor II (20209C>T and 20210G>A), factor V Leiden (1691G>A) and MTHFR (677C>T) mutations in the index patient 
and in !rst-degree family members.
FIGURE 1. Results for index patient using two di"erent meth-
ods.
(A). Results for patient blood sample analysed by the PTH-FV-
MTHFR StripAssay (ViennaLab) method. In 20209C>T homozy-
gous cases, no blue band is observed in the strip. (B). Result ob-
tained with the Xpert® HemosIL® Factor II & Factor V Assay.
a
b
in the patient’s parents and brother, homozygous 
20209C>T was detected in the patient’s sister and 
heterozygous 20209C>T status was con!rmed for 
the patient’s son and daughter (Table 1).
Figure 2 shows the results by Real time-PCR meth-
od (Light-Cycler) for the samples analysed for the 
index case, his parents and brother, indicating the 
patient’s homozygosis status. Figure 3 shows the 
FIGURE 2. DNA melting curves for the patient and !rst-degree 
relatives obtained using LightCycler. The melting curve of the 
heterozygous for 20209 C>T demonstrates peaks at 87 ºC and 
81 ºC. Patient homozygous for 20209C>T presents one peak at 
87ºC.
direct DNA sequencing for the patient and his par-
ents.
Thirty control patients samples (patients without 
thrombotic problems) were analyzed and did not 
show the mutation 20209C>T heterozygous or ho-
mozygous status.
Because they are from the same village, the par-
ents are probably consanguineous. The patient 
and his brother and sister are also 677C>T hetero-
zygous. The homozygous presence of the 677C>T 
mutation, as well as being heterozygous for 
http://dx.doi.org/10.11613/BM.2014.018 Biochemia Medica 2014;24(1):159–66 
  163
Izquierdo Álvarez S. et al. Deep vein thrombosis by 20209C>T prothrombin gene
20209C>T, in the father of the index case may ex-
plain his clinical signs: thrombophlebitis. The pres-
ence of homozygous 20209C>T was the probable 
cause of the patient’s deep vein thrombosis and 
the association with heterozygous 677C>T may in-
crease the risk of thrombotic events. The patient’s 
sister has the same mutations as the index case 
and has got some symptoms (frequent bruising, 
varicose veins), so that knowing the presence of 
this mutation will help prevent thrombotic events 
in this patient The two subjects with homozygous 
20209C>T mutations have children and so will 
need genetic counselling (see pedigree, Figure 4).
FIGURE 3. Direct DNA sequence analysis with designed primers to identify the 20209C>T mutation in the index case.
(A). Sequence analysis for the patient in the forward direction shows only one peak (red) at prothrombin nucleotide position 20209. 
The grey arrow shows that the DNA is homozygous for a C to T mutation at position 20209. (B). Sequence analysis for the patient’s 
father in the forward direction shows two overlapping peaks (the blue peak corresponds to C and the red peak corresponds to T) 
at prothrombin nucleotide position 20209, which means that this individual is heterozygous for the 20209C>T mutation. (C). Se-
quence analysis for the patient’s mother in the forward direction shows two overlapping peaks (the blue peak corresponds to C and 
the red peak corresponds to T) at prothrombin nucleotide position 20209, which means that this individual is heterozygous for the 
20209C>T mutation.
a
b c
FIGURE 4. Pedigree with the results for 20209C>T for family 
members.
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Discussion
We found that the patient had a homozygous C>T 
mutation at position 20209; this interfered with 
the PCR product, which needs a C at this position 
to be able to bind to the wild-type probe present 
in the test strip (Vienna Lab method). If this patient 
had not been studied using the Vienna Lab meth-
od, the presence of 20209 C>T would not have 
been detected.
The 20209C>T mutation in samples gave unusual 
genotyping results in laboratories that participate 
in external quality assurance (EQA) programmes 
(20). The fact that the pyrosequencing method 
was not able to detect the 20209C>T mutation 
con!rms other reports that some methods are un-
able to detect the presence of this mutation (19).
We have no found presence of 20209C>T variant in 
our control group (thirty samples). In the literature 
has been described the incidence of the pro-
thrombin 20209C>T variant in a case control study 
of risk factors for venous thromboembolism in Af-
rican-American and Caucasian populations. The 
incidence in African-Americans was 0.7% in con-
trols versus 1.3% in cases and in the Caucasian 
population, one patient was found to be hetero-
zygous in the control group and none in the study 
group (9). Another study of a black population 
with thrombosis reported incidences of 4.9% (4/81) 
(11) and of 1.6% (1/61) (21). Patients with hetero-
zygous prothrombin 20209C>T present a risk fac-
tor for venous thromboembolism. Hereditary 
thrombophilia has autosomal dominant inherit-
ance pattern and is associated with an increased 
risk of venous thrombosis: de!ciency of anti-
thrombin III, protein C, or free protein S, or factor V 
Leiden, or mutations in phrotrombin gene. The 
classic prothrombin mutation associated with an 
increased thrombotic risk is a G to A substitution 
at position 20210 of the prothrombin gene. The 
20209C>T mutation may also be associated with 
thrombosis (9,22).
Some studies reported that elevated plasma pro-
thrombin activity not appeared in patients with 
20209C>T mutations, whereas recent studies have 
shown that this mutation is associated with gain-
of-function of 3´end processing and upregulation 
of prothrombin protein expression (15). The case 
index, homozygous for the 20209C> T mutation, 
had not elevated levels of prothrombin which was 
in agreement with that described in the literature. 
Likewise, the sister of the index case homozygous 
for the 20209C> T mutation and the other studied 
!rst-degree relatives who were heterozygous for 
this mutation showed no elevated levels of pro-
thrombin or alteration in any of the hypercoagula-
ble study parameters. Another study showed a 
contradictory outcome for in vitro functional stud-
ies of the 20209C>T variant (12).
The patient’s parents were both 20209C>T hetero-
zygous and this mutation could explain the moth-
er’s acute myocardial infarction and the father’s 
thrombophlebitis (20209C>T heterozygous plus 
677C>T homozygous). The patient’s brother was 
20209C>T heterozygous and asymptomatic and 
the patient’s sister was 20209C>T homozygous 
and symptomatic (bruising and varicose veins).
Conclusions
In the index case described in this work could jus-
tify the phenomenon of deep vein thrombosis by 
the presence of the mutation 20209C>T in ho-
mozygosity and also in the presence of the muta-
tion 677C>T in heterozygosity because the combi-
nation of mutations would increase the risk of 
thrombosis.
Larger and population-speci!c studies of Spanish 
individuals with thrombotic (especially patients 
with deep vein thrombosis and with screening of 
the three common mutations associated with 
thrombosis negative) and/or obstetric complica-
tions will be necessary to establish the true preva-
lence of the 20209C>T mutation and evaluate the 
thrombotic and/or obstetric consequences. The 
presence of the mutation 20209C>T both ho-
mozygous and heterozygous in combination with 
the presence of the mutation 677C>T hetero-
zygous or homozygous might be a risk factor to 
consider in the face of su"ering a possible throm-
botic event. Suitable genetic counselling should 
be provided to the patient and !rst-degree rela-
tives (siblings and o"spring of childbearing age) as 
it important to detect prothrombin gene variants 
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that could increase their risk for thrombotic 
events.
The possibility of including 20209C>T mutation 
detection in screening for the most common mu-
tations associated with thrombotic events should 
be considered.
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